Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year in the U.S. To develop a consistent method of estimating prostate cancer size, ...

Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year in the U.S. To develop a consistent method of estimating prostate cancer size, ...

Brachytherapy and proton therapy are radiation therapies, while HIFU and TULSA are focal therapies with distinct mechanisms. Medicare typically covers HIFU but not TULSA, with potential future ...

Prostate cancer is one of the most common malignancies affecting men globally, usually developing within the prostate gland. While in its early stages, the disease is often confined to the gland ...

For years, prostate cancer specialists hit a wall when prostate-specific antigen (PSA) levels crept up after definitive treatment. The cancer was likely back — but where? And to what extent? Bone plus ...

An implantable microdevice safely delivered multiple drugs directly into prostate cancer lesions, enabling assessment of tumor-specific responses. All 14 patients successfully underwent robot-assisted ...

PSMA-PET imaging has higher sensitivity than conventional imaging and can detect radiorecurrent prostate cancer at lower PSA levels. PSMA-PET imaging can detect radiorecurrent prostate cancer lesions ...

The Department of Urology at Seoul National University Bundang Hospital announced that it has introduced the first micro ultrasound equipment in Korea that can evaluate prostate tumors through ...

Following elevated PSA levels and subsequent tests, the author was diagnosed with prostate cancer. Post-treatment, the author's PSA levels returned to the normal range. The author encourages regular ...